MétaCan
Menu
Back to cohort
Record W4386465677 · doi:10.1093/jcag/gwad013

The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations—IBD in Seniors

2023· review· en· W4386465677 on OpenAlexafffundabout
Seth R. Shaffer, M Ellen Kuenzig, Joseph W. Windsor, Alain Bitton, Jennifer Jones, Kate Lee, Sanjay K. Murthy, Laura E. Targownik, Juan Nicolás Peña-Sánchez, Noelle Rohatinsky, Sara Ghandeharian, Parul Tandon, Joëlle St‐Pierre, Navneet Natt, Tal Davis, Jake Weinstein, James Im, Eric I. Benchimol, Gilaad G. Kaplan, Quinn Goddard, Julia Gorospe, Maxime Bergevin, Ken Silver, D. E. Bowles, Margaret M. Stewart, Marsha Pearlstein, Elizabeth H Dawson, Çharles N. Bernstein

Bibliographic record

VenueJournal of the Canadian Association of Gastroenterology · 2023
Typereview
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsInstitut Universitaire de Gériatrie de MontréalPublic Health OntarioNOSM UniversityUniversité de MontréalUniversity of SaskatchewanUniversity of CalgaryMount Sinai HospitalInstitute for Clinical Evaluative SciencesMcGill University Health CentreUniversity of OttawaCrohn's and Colitis CanadaUniversity of TorontoSickKids FoundationDalhousie UniversityUniversity Health NetworkOttawa HospitalUniversity of Manitoba
FundersJanssen CanadaPfizer CanadaAbbVie CanadaTakeda FoundationAmgen CanadaAmgenPfizerBristol-Myers Squibb CanadaBristol-Myers Squibb
KeywordsMedicineInflammatory bowel diseasePolypharmacyDiseaseUstekinumabUlcerative colitisCrohn's diseaseHealth careVedolizumabIntensive care medicineInternal medicineAdalimumab

Abstract

fetched live from OpenAlex

Approximately one out of every 88 seniors has inflammatory bowel disease (IBD), and this is expected to increase in the future. They are more likely to have left-sided disease in ulcerative colitis, and isolated colonic disease in Crohn's disease; perianal disease is less common. Other common diagnoses in the elderly must also be considered when they initially present to a healthcare provider. Treatment of the elderly is similar to younger persons with IBD, though considerations of the increased risk of infections and malignancy must be considered when using immune modulating drugs. Whether anti-TNF therapies increase the risk of infections is not definitive, though newer biologics, including vedolizumab and ustekinumab, are thought to be safer with lower risk of adverse events. Polypharmacy and frailty are other considerations in the elderly when choosing a treatment, as frailty is associated with worse outcomes. Costs for IBD-related hospitalizations are higher in the elderly compared with younger persons. When elderly persons with IBD are cared for by a gastroenterologist, their outcomes tend to be better. However, as elderly persons with IBD continue to age, they may not have access to the same care as younger people with IBD due to deficiencies in their ability to use or access technology.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.503
Threshold uncertainty score0.987

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0030.004
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0080.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.263
Teacher spread0.251 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations14
Published2023
Admission routes3
Has abstractyes

Explore more

Same venueJournal of the Canadian Association of GastroenterologySame topicInflammatory Bowel DiseaseFrench-language works237,207